Literature DB >> 19307926

Neurogenin 3 and neurogenic differentiation 1 are retained in the cytoplasm of multiple endocrine neoplasia type 1 islet and pancreatic endocrine tumor cells.

Margareta H Lejonklou1, Katarina Edfeldt, Térèse A Johansson, Peter Stålberg, Britt Skogseid.   

Abstract

OBJECTIVES: To investigate if transcription factors involved in pancreatic differentiation and regeneration are present in pancreatic endocrine tumors and if they are differentially expressed in normal pancreas compared with multiple endocrine neoplasia type 1 (MEN1) nontumorous pancreas.
METHODS: The expression of neurogenin 3 (NEUROG3), neurogenic differentiation 1 (NEUROD1), POU class 3 homeobox 4 (POU3F4), pancreatic duodenal homeobox factor 1 (PDX1), ribosomal protein L10 (RPL10), delta-like 1 homolog (Drosophila; DLK1), and menin was analyzed by immunohistochemistry in normal pancreas and pancreatic endocrine tumors from 6 patients with MEN1 and 16 patients with sporadic tumors, as well as pancreatic specimens from Men1 heterozygous and wild type mice. Quantitative polymerase chain reaction was performed in a subset of human tumors.
RESULTS: Tumors and MEN1 nontumorous endocrine cells showed a prominent cytoplasmatic NEUROG3 and NEUROD1 expression. These factors were significantly more expressed in the cytoplasm of Men1 heterozygous mouse islet cells compared with wild type islets; the latter showed an exclusively nuclear reactivity. The degree of Pou3f4, Rpl10, and Dlk1 immunoreactivities differed significantly between islets of heterozygous and wild type mice. The expressions of RPL10 and NEUROD1 were prominent in the MEN1 human and heterozygous mouse exocrine pancreas. Insulinomas had significantly higher PDX1 and DLK1 messenger RNA levels compared with other tumor types.
CONCLUSIONS: Transcription factors involved in pancreatic development show altered expression and subcellular localization in MEN1 nontumorous pancreas and pancreatic endocrine tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19307926     DOI: 10.1097/MPA.0b013e3181930818

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.

Authors:  Gratiana Hermann; Björn Konukiewitz; Anja Schmitt; Aurel Perren; Günter Klöppel
Journal:  Virchows Arch       Date:  2011-07-08       Impact factor: 4.064

Review 2.  Neuroendocrine neoplasms of the gut and pancreas: new insights.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2011-08-02       Impact factor: 43.330

3.  Altered MENIN expression disrupts the MAFA differentiation pathway in insulinoma.

Authors:  Z Hamze; C Vercherat; A Bernigaud-Lacheretz; W Bazzi; R Bonnavion; J Lu; A Calender; C Pouponnot; P Bertolino; C Roche; R Stein; J Y Scoazec; C X Zhang; M Cordier-Bussat
Journal:  Endocr Relat Cancer       Date:  2013-10-24       Impact factor: 5.678

Review 4.  Inactivation of X-linked tumor suppressor genes in human cancer.

Authors:  Runhua Liu; Mandy Kain; Lizhong Wang
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

Review 5.  Cellular origins of beta-cell regeneration: a legacy view of historical controversies.

Authors:  A Granger; J A Kushner
Journal:  J Intern Med       Date:  2009-10       Impact factor: 8.989

6.  Differential Morphological Diagnosis of Various Forms of Congenital Hyperinsulinism in Children.

Authors:  Lubov Borisovna Mitrofanova; Anastasia Arkadyevna Perminova; Daria Viktorovna Ryzhkova; Anna Andreyevna Sukhotskaya; Vladimir Gireyevich Bairov; Irina Leorovna Nikitina
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-23       Impact factor: 5.555

7.  A CRM1-mediated nuclear export signal is essential for cytoplasmic localization of neurogenin 3 in neurons.

Authors:  Julia Simon-Areces; Estefania Acaz-Fonseca; Isabel Ruiz-Palmero; Luis-Miguel Garcia-Segura; Maria-Angeles Arevalo
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.